KR101909869B1 - Injection liquid composition for localized lipolysis and smart mixing system for it - Google Patents

Abstract

The present invention relates to an injection composition for localized lipolysis, which comprises 50 cc of normal saline, 30 mg of lidocaine, 120 mg of aminophylline, 300 to 600 IU of hyaluronidase, 200 mg of vitamin C and 10 mg of pentoxifylline, and thus weight reduction and maintenance of a proper body shape can be achieved by promoting reduction of local adipose tissue.

Description

TECHNICAL FIELD The present invention relates to an injectable composition for local fat decomposition and a smart composition system thereof.

The present invention relates to an injectable composition for topical fat decomposition and a smart composition system thereof.

Korean Patent Laid-Open No. 10-2017-0113520 (Laid-open date: October 12, 2017, entitled "Injection composition for removing local fat") contains hyaluronidase in 300 IU to 600 IU units and is administered as a local anesthetic The present invention relates to a pharmaceutical composition comprising 0.08 to 0.4% by weight of lidocain, 0.01 to 0.02% by weight of peniramine as an antihistamine, 0.01 to 4.0% by weight of L-carnitine as a fat decomposition accelerator, And 0.1% to 2.0% by weight of water, and the remaining physiological saline solution, wherein the injection amount is 0.5 to 2 cc and the injection point interval is 0.5 to 1.5 cm.

Wherein the composition comprises 10 to 40% by weight of the deoxycholic acid and 01 to 50% by weight of the levocarnitine, based on 100% by weight of the whole injectable composition, of deoxycholic acid and levocarnitine, And 10 to 30% by weight of the deoxycholic acid and 01 to 20% by weight of the levocarnitine.

Such a conventional technique claims that a satisfactory level of fat removal effect can be obtained even by a non-surgical method. However, since such an injectable composition is compounded or mixed by a physician or a nurse, it is not easy to realize a precise composition, There has been a problem that the risk of misuse or abuse remains due to human error.

It is an object of the present invention, which is created to solve the above-mentioned problems, to promote reduction of local adipose tissue to achieve weight loss and proper body shape maintenance, and to precisely control the composition of injections for local fat decomposition, And to provide a smart composition system and an injectable composition for local fat decomposition which can fundamentally solve human errors.

SUMMARY OF THE INVENTION It is an object of the present invention to provide a medicine dispenser having a casing body, a casing having a main door provided on one side of the casing body, and a medicine container insertion portion provided with a plurality of insertion holes formed on an upper surface of the casing body; An upper cover provided on an upper surface of the casing body to open and close the medicine container insertion portion; And an inflow pipe communicating with an upper end of the backflow preventing infuser body and penetrating through the insertion hole of the inflow preventing infuser body and protruding upward; A plurality of medicament passages in which the inflow pipe is inserted into the inner periphery of the opened lower portion and the outer periphery of the opened lower portion is inserted into and inserted into the insertion hole; A pump communicating with the medicament inflowing devices; A main injection container built in the casing main body adjacent to the main door; A main control valve provided between a flow path for communicating the pump and the main injection agent container; A first opening / closing valve provided between the fluid inlet and the flow path communicating the pump, respectively; A second on-off valve provided between the main control valve and the main infusion container; A plurality of cover detection sensors provided on an upper surface of the casing main body which is in contact with a lower end portion of the upper cover for detecting normal mounting or detachment of the upper cover; And a controller provided on a front surface of the casing main body for controlling the medicine infuser, the pump, the main control valve, the first and second opening / closing valves, and the cover detection sensor, ≪ / RTI >

Preferably, the apparatus further includes a door actuator provided at an upper end of the main door of the present invention, further comprising a sub injector container embedded in the casing main body adjacent to the main door, Further comprising a third open / close valve provided between the main control valve and the sub-injection container, and a third open / close valve provided between the main control valve and the waste liquid recovery container, Further comprising a fourth opening and closing valve provided in the casing and including a weight sensing sensor built in the casing body so as to be positioned on a lower surface of the waste liquid collecting container and configured to communicate with a flow path for communicating the second opening and closing valve and the pump Further comprising a cleaning agent inlet provided on one side of the casing body, wherein the cleaning agent inlet and the second Closing valve, the fifth open / close valve, the fifth open / close valve, and the weight detection sensor are connected by the controller to the door actuator, the third open / close valve, Is controlled.

Preferably, the casing of the present invention further comprises a label withdrawal door provided on the casing main body, and a label printer incorporated in the casing main body, which is controlled by the controller to be positioned behind the label withdrawal door, .

Another object of the present invention is to provide a pharmaceutical composition comprising 50 cc of normal saline, 30 mg of lidocaine, 120 mg of aminophylline, 300 to 600 IU of hyaluronidase, 200 mg of vitamin C and 10 mg of pentoxifylline according to any one of the above systems Or a pharmaceutically acceptable salt thereof.

Preferably, the hyaluronidase of the present invention is 450 IU units.

As described above, the present invention promotes reduction of local adipose tissue, thereby achieving weight loss and proper body shape retention.

In addition, the present invention can be produced by precisely and rapidly compounding an injectable injection for local fat decomposition, which is frequently performed, and the name of the patient to be treated, the composition of the injection, and the like are displayed in the container for injecting the local fat decomposition. There is a characteristic that human error can be cut off at the source.

1 is a perspective view showing a smart composition system of an injectable injection for local fat decomposition according to the present invention.
Fig. 2 is a perspective view showing a state in which the top cover of the smart composition system of the injectable injection for local fat decomposition of Fig. 1 is detached. Fig.
Fig. 3 is a schematic diagram showing the configuration of Fig.
FIG. 4 is a perspective view showing an injectable container for local fat decomposition filled with an injection agent by the smart composition system of the injection for local fat decomposition of FIG. 1; FIG.

Hereinafter, embodiments of the present invention will be described with reference to the drawings.

First, hyaluronidase (Mucinase) is an enzyme that hydrolyzes hyaluronic acid, which has a high viscosity that fills the intercellular space. It lowers intercellular viscosity and causes diffusion and absorption of drugs during subcutaneous or intramuscular injection Penetration ability) 3 ~ 5 times, and it plays a role of softening tissues and joints by decomposing the adhesive binding substance. In addition, hyaluronidase is an enzyme that inhibits proliferation of fibrous tissue to reduce pain, and promotes reabsorption of body fluids and blood that are present in tissues excessively.

This hyaluronidase is injected into a tube about 2 cm above the injection needle when injecting 1,500 IU unit in 1 ml injection water or physiological saline solution before starting subcutaneous injection. 1,500 IU is appropriate when 500-1,000 ml of sap is administered. Care should be taken in children and elderly people to carefully control the rate and total dose of the infusion solution. Especially, in case of kidney failure, care should be taken not to overhydrate.

In addition, hyaluronidase may cause localized irritation, redness, pain, irritation, shortness of breath, shortness of breath, shock, respiratory arrest, Diffusion of infection, bleeding and bruising may occur, so care should be taken.

The topical fat injection composition of the present invention containing hyaluronidase having a local fat decomposition effect is composed of 50 mg of normal saline, 30 mg of lidocaine, 120 mg of aminophylline, 400 to 470 IU of hyaluronidase, 200 mg of vitamin C and 10 mg of pentoxifylline .

Test for lipidation effect of topical lipid-degrading injectable composition

The local fat-decomposing effect of the present invention is realized by hyaluronidase. In all of Examples 1 to 3, compositions other than hyaluronidase were all formed as shown in Table 1 below.

Here, the normal saline is physiological saline, the lidocaine is the local anesthetic agent, the aminophylline is the accelerator for promoting the lipolysis of the hyaluronidase, and the pentoxifylline is the blood circulation improving agent.

The 10-year-old woman who had a BMI of 30 and who had the same diet as the usual diabetic patient was a 20-year-old woman without a chronic disease (waist circumference 110 ± 0.2 cm). The injection procedure was performed from 1 cm below the umbilicus , 11 cm apart from each other by a distance of 1 cm to the right and 11 cm apart from the 2 cm below the navel, 11 cm apart from the 5 cm distal from the navel by the same method as above, 4 cm, and 5 cm from left to right in the same manner as above. 11 sections (total 55 sections) from the 5 cm distal to the opposite ends were divided into 5 groups. After 5 doses of InBody, The decrease in waist circumference was measured using an InBody 770 of the same manufacturer and the average value was recorded in Table 2 below.

Here, in Examples 1 to 3, using the Ultralipo device using High Intensity Focused Ultrasound (HIFU) of Wintec Korea, before or after the procedure, Stimulation for 40 minutes.

First, Wintek's ultra-lipoic is from sikyak treatment "means a Body Mass Index BMI of 30kg / cm ² or less to a, in the case of the person than the abdominal fat thickness 2.5cm device to assist in the reduction of abdominal circumference average 2cm and out 'as permitted , And it transfers the ultrasonic energy of 2Mhz to the depth of 13mm inside the skin to decompose the fat in the body.

In particular, the HIFU method does not have the burden of surgery due to non-surgical treatment, unlike the facial elevation method, and it can control the depth of energy transfer (reaching the SMAS layer) according to the cartridge and can not effectively transmit energy from the epidermis to the dermis. This method has a merit of eliminating the disadvantages, and it is an excellent advantage because it maintains up to 1 year compared to the laser method which has only 3 ~ 6 weeks of surgery / surgery effect.

Here, the HIFU method is preferably performed after injecting injectable injection for local fat decomposition. The gel is uniformly applied to the treatment site, and the handpiece of the HIFU device is closely attached to the treatment site. Then, the HIFU is irradiated for 20 minutes, To necrotize fat, and necrotic fat is naturally released by urine, sweat, and the like.

As shown in Table 2, in Examples 1, 2 and 3, it was confirmed that the average waist circumference decreased by 13.9 cm, 14.7 m and 13.6 cm after the final treatment, It has been proved that there is a harm effect.

1 to 4, a smart composition system 100 for injecting an agent for local fat decomposition according to the present invention comprises a casing 10, an upper cover 20, a drug infuser 30, a drug container MB, The main injection valve Vm, the sub injection container Vs, the waste liquid collecting container Vw, the pump P, the main control valve MV, and the main control valve MV are connected to the cleaning agent supply port Wi, the door actuator Dact, the display panel PN, A cover detection sensor S1, a weight detection sensor S2, a label printer PRN, and a controller CTB. The first to fifth open / close valves V1 to V5,

The casing 10 includes a casing main body 11, a main door 13 provided on one side of the casing main body 11, a label withdrawal door 15 provided on the casing main body 11 on the front side, And a medicine container insertion part 17 provided with a plurality of insertion holes 17a formed on the upper surface of the medicine container insertion part 17.

Here, the casing main body 11 is formed in the space portion inside, and the upper portion of the front surface is formed to be inclined.

The upper cover 20 is provided on the upper surface of the casing main body 11 so as to open and close the medicine container insertion portion 17. Here, the upper cover 20 is preferably made of a transparent synthetic resin material so that the inner structure can be visually confirmed.

The door actuator (Dact) is provided at the upper end of the main door (13). Here, the door actuator Dact has a structure in which the lower end of the door actuator Dact is opened and closed while the upper end of the hinged main door 13 is rotated as shown in FIG. Since the door actuator Dact corresponds to known components, a detailed description thereof will be omitted.

The medicine inflow device 30 includes a backflow preventing infuser body 31 built in a lower portion of the medicine container insertion portion 17 and a backflow preventing infuser main body 31 communicating with the upper end of the backflow preventing infuser main body 31, And an inflow pipe 33 protruding upwardly from the bottom wall 17a.

Here, the medicine introducer 30 is provided with six insertion holes 17a one by one.

33a is an inflow hole of the inflow pipe 33. [

The medicine container MB is inserted into the inner tube of the lower opened portion of the drug infuser 30 and the outer peripheral portion of the opened lower portion is inserted into the insertion hole 17a and inserted therein.

Here, the drug reservoir (MB) is filled with normal saline (N / S), lidocaine, aminophylline, hyaluronidase, vitamin C and pentoxifylline, and other drugs And may be added or excluded.

The pump (P) is in communication with each drug inflow (30).

The main injection container Vm is built in the casing main body 11 adjacent to the main door 13. [

The sub-injection container Vs is built in the casing main body 11 adjacent to the main door 13. Here, the sub-injection container Vs is disposed at a position adjacent to the main injection container Vm.

The waste liquid collection container Vw is built in the casing main body 11 adjacent to the main door 13. [ Here, the sub-injection container Vs is disposed at a position adjacent to the sub-injection container Vs.

Although the main injecting container Vm, the sub-injection container Vs and the waste liquid collecting container Vw are arranged one by one in the present embodiment, the present invention is not limited to this, I will reveal it in advance.

The main control valve MV is provided between the respective passages for communicating the pump P with the main injection container Vm, the sub-injection container Vs and the waste liquid collection container Vw.

Here, the main control valve MV has a basic position for communicating the pump P and the waste liquid collection container Vw, a first position for communicating the pump P and the main injection container Vm, And the sub-injection container (Vs).

The first on-off valve V1 is provided in each of the flow paths for communicating the respective chemical infusers 30 and the pump P. [

The second on-off valve V2 is provided in a flow path for communicating the main control valve MV with the main injection container Vm.

The third on-off valve V3 is provided in a flow path for communicating the main control valve MV and the sub-injection container Vs.

The fourth opening / closing valve V4 is provided in a flow path for communicating the main control valve MV and the waste liquid collecting container Vw.

The cleaning agent input port Wi is provided on one side of the casing main body 11 so as to communicate with the flow path for communicating the second opening and closing valves V2 and the pump P. [

The fifth opening / closing valve V5 is provided in a flow path for communicating the cleaning agent inlet Wi with the second opening / closing valve V2. Therefore, the fifth on-off valve V5 controls to flow into or out of the flow path for communicating the second on-off valves V2 and the pump P.

The cover detection sensor S1 is provided on the upper surface of the casing main body 11 to which the lower end of the upper cover 20 is contacted. Here, the cover detection sensor S1 is provided at least two spaced apart to detect the normal attachment or detachment of the upper cover 20.

The weight detection sensor S2 is built in the casing main body 11 so as to be positioned on the lower surface of the waste liquid collection container Vw. Here, the weight detection sensor S2 is provided for measuring the weight of the waste liquid collection container Vw.

The display panel (PN) is provided on the inclined front surface of the casing body (11).

The label printer PRN is built in the casing main body 11 so as to be located behind the label withdrawal door 15. Here, the label LLs output by the label printer PRN is drawn out by lifting the label withdrawal door 15. [ Since the label printer PRN is a well-known apparatus, a detailed description thereof will be omitted.

The controller CTB includes a door actuator Dact, a chemical infuser 30, a pump P, a main control valve MV, a display panel PN, a label printer PRN, V1 to V5, the cover detection sensor S1 and the weight detection sensor S2, respectively, on the inclined front surface of the casing main body 11. [

Here, although the controller (CTB) is shown as being composed of a keyboard and a jog dial, it is noted that various modifications can be made in accordance with the purpose of use.

Hereinafter, the operation of the smart composition system 100 of the injectable injection for local fat decomposition having the above-described structure will be briefly described. First, the first to fifth open / close valves V1 to V5 are closed, and a label roll (no number) is wound around the label printer PRN. Further, it is preferable that all relations of the smart composition system 100 of injectable injection for local fat decomposition of the present embodiment are displayed on the display panel (PN).

① Operate the controller (CTB) to supply power to all electrical products.

(2) After the upper cover 20 is opened, a medicine container MB corresponding to each medicine container MB is inserted into the medicine infuser 30, and then the medicine container MB is covered.

(3) After opening the first and second opening / closing valves V1, the main control valve MV is switched to the first position.

(4) The pump P is operated to pump the medicine filled in the medicine container MB and fill it with the main injection container Vm. At this time, the controller CTB controls the medicine introducer 30 to supply the required medicine from each medicine container MB through the flow path, and then closes the first on-off valve V1. Here, as many medicines as necessary are set in advance in the controller (CTB) as a default value, and the controller (CTB) is controlled manually when the user (usually a doctor) prescribes otherwise.

(5) When the medicine is filled in the main injection agent container (Vm), completion of compounding is displayed on the display panel (PN). At the same time, the label printer PRN outputs the labels LLs according to the prescribed composition table.

(6) When the main door 13 is opened by the door actuator Dact by operating the controller CTB, the main injection container Vm is detached and the label LLs output together with the main injection container Vm is taken out from the label withdrawal door 15 do.

(7) Finally, attaching the label LLs to the outer periphery of the main injection container Vm completes all the operations (see FIG. 4).

In the case of cleaning the smart composition system 100 of injectable injection for local fat decomposition after the completion of the operation, a cleaning liquid supply device (not shown) is connected to the cleaning agent input port Wi and then a controller (CTB) The opening / closing valve V1 is opened, and the main control valve MV is switched to the basic position so that the waste liquid in which the flow path is cleaned is filled in the waste liquid collecting container Vw. At this time, the weight detection sensor S2 senses the weight of the waste liquid collection container Vw.

Here, when the cleaning liquid supply device supplies the cleaning liquid at a high pressure, it is not necessary to operate the pump P, but when the supply pressure of the cleaning liquid is low, the pump P may be operated and used.

Then, if the weight value inputted from the weight detection sensor S2 is judged by the controller CTB that the waste liquid collecting container Vw is fully charged, it indicates completion of cleaning on the display panel PN. At this time, before separating the cleaning liquid supply device, the controller CTB closes the fifth opening / closing valve V5 to originally block the supply of the cleaning liquid through the flow path, and then separates the cleaning liquid supply device. It should be noted that the cleaning liquid may be selected depending on the purpose of use, such as purified water, alcohol, and the like.

Thereafter, the waste solution collecting container Vw is separated and the cleaning operation is completed.

The injectable composition for local fat decomposition produced by this system and method is filled in a main injection container Vm and its composition is shown in the label LLs as 50 cc of Half N / S, 30 mg of lidocaine, 120 mg of aminophylline, 400 to 470 IU of hyaluronidase, 200 mg of vitamin C and 10 mg of pentoxifylline.

While the present invention has been described with reference to exemplary embodiments, it is to be understood that the invention is not limited to the disclosed exemplary embodiments.

10: casing 20: upper cover
30: drug infusion machine
CTB: Controller Dact: Door actuator
MB: Pharmaceutical box MV: Main control valve
V1 to V5: Opening and closing valve
S1: Cover detection sensor S2: Weight detection sensor
100: Smart composition system of injection for local fat decomposition

Claims (5)

A casing having a casing main body, a main door provided on one side surface of the casing main body, and a medicine bar insertion portion provided with a plurality of insertion holes formed on an upper surface of the casing main body;
An upper cover provided on an upper surface of the casing body to open and close the medicine container insertion portion;
And an inflow pipe communicating with an upper end of the backflow preventing infuser body and penetrating through the insertion hole of the inflow preventing infuser body and protruding upward;
A plurality of medicament passages in which the inflow pipe is inserted into the inner periphery of the opened lower portion and the outer periphery of the opened lower portion is inserted into and inserted into the insertion hole;
A pump communicating with the medicament inflowing devices;
A main injection container built in the casing main body adjacent to the main door;
A main control valve provided between a flow path for communicating the pump and the main injection agent container;
A first opening / closing valve provided between the fluid inlet and the flow path communicating the pump, respectively;
A second on-off valve provided between the main control valve and the main infusion container;
A plurality of cover detection sensors provided on an upper surface of the casing main body which is in contact with a lower end portion of the upper cover for detecting normal mounting or detachment of the upper cover;
And a controller provided on a front surface of the casing main body to control the medicine inflow device, the pump, the main control valve, the first and second open / close valves, and the cover detection sensor,
Further comprising a door actuator provided at an upper end of the main door,
Further comprising a sub-injector vessel embedded in the casing main body adjacent to the main door,
Further comprising a waste liquid collecting container embedded in the casing main body adjacent to the main door,
Further comprising a third on-off valve provided between the main control valve and the sub-injection container,
Further comprising a fourth open / close valve provided between the main control valve and the flow path for communicating the waste liquid collecting container,
Further comprising a weight detection sensor built in the casing body to be positioned on a lower surface of the waste liquid collection container,
Further comprising a cleaning agent inlet provided on one side of the casing body so as to communicate with a flow path for communicating the second opening / closing valve and the pump,
And a fifth open / close valve provided between the flow path for communicating the cleaning agent input port and the second open / close valve,
Wherein the controller controls the door actuator, the third opening / closing valve, the fourth opening / closing valve, the fifth opening / closing valve, and the weight detecting sensor.
delete The method according to claim 1,
Wherein the casing further comprises a label withdrawal door provided on the front surface of the casing body,
Further comprising a label printer incorporated in the casing main body, the label printer being controlled by the controller to be positioned behind the label withdrawal door.
An injectable composition for local fat decomposition comprising 50 cc of normal saline, 30 mg of lidocaine, 120 mg of aminophylline, 400 to 470 IU of hyaluronidase, 200 mg of vitamin C and 10 mg of pentoxifylline according to the system of claim 1 or 3.
5. The method of claim 4,
Wherein the hyaluronidase is 450 IU units.

Images